Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform products primarily for the treatment of neuroinflammation. It is developing JNS101 which is in Phase II trials for the treatment of Friedreich's Ataxia, a rare inherited disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis type 1. The company is also developing JNS108 which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer’s disease; and JNS107, which is in Phase II trials for the treatment of mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; and JNS110 for traumatic brain injury/concussion. Jupiter Neurosciences, Inc. was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was incorporated in 2015 and is based in Jupiter, Florida.